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IMPORTANCE Endoscopic placement of multiple plastic stents in parallel is the first-line
treatment for most benign biliary strictures; it is possible that fully covered, self-expandable
metallic stents (cSEMS) may require fewer endoscopic retrograde cholangiopancreatography
procedures (ERCPs) to achieve resolution.
OBJECTIVE To assess whether use of cSEMS is noninferior to plastic stents with respect to
stricture resolution.
DESIGN, SETTING, AND PARTICIPANTS Multicenter (8 endoscopic referral centers), open-label,
parallel, randomized clinical trial involving patients with treatment-naive, benign biliary
strictures (N = 112) due to orthotopic liver transplant (n = 73), chronic pancreatitis (n = 35),
or postoperative injury (n = 4), who were enrolled between April 2011 and September 2014
(with follow-up ending October 2015). Patients with a bile duct diameter less than 6mm and
those with an intact gallbladder in whom the cystic duct would be overlapped by a cSEMS
were excluded.
INTERVENTIONS Patients (N = 112) were randomized to receive multiple plastic stents or a
single cSEMS, stratified by stricture etiology and with endoscopic reassessment for resolution
every 3months (plastic stents) or every 6months (cSEMS). Patients were followed up for 12
months after stricture resolution to assess for recurrence.
MAIN OUTCOMES ANDMEASURES Primary outcomewas stricture resolution after nomore
than 12 months of endoscopic therapy. The sample size was estimated based on the
noninferiority of cSEMS to plastic stents, with a noninferiority margin of −15%.
RESULTS There were 55 patients in the plastic stent group (mean [SD] age, 57 [11] years;
17 women [31%]) and 57 patients in the cSEMS group (mean [SD] age, 55 [10] years; 19
women [33%]). Compared with plastic stents (41/48, 85.4%), the cSEMS resolution rate was
50 of 54 patients (92.6%), with a rate difference of 7.2% (1-sided 95% CI, −3.0% to;
P < .001). Given the prespecified noninferiority margin of −15%, the null hypothesis that
cSEMS is less effective than plastic stents was rejected. Themean number of ERCPs to
achieve resolution was lower for cSEMS (2.14) vs plastic (3.24; mean difference, 1.10; 95% CI,
0.74 to 1.46; P < .001).
CONCLUSIONS AND RELEVANCE Among patients with benign biliary strictures and
a bile duct diameter 6mm ormore in whom the coveredmetallic stent would not overlap
the cystic duct, cSEMSwere not inferior to multiple plastic stents after 12 months in achieving
stricture resolution. Metallic stents should be considered an appropriate option in patients
such as these.
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E ndoscopic retrogradecholangiopancreatography(ERCP)is the primary method for access to the pancreatobili-ary system. Among the principal indications for stent
placement is benign bile duct strictures, for which ERCP has
become the preferred first-line treatment strategy.1 Endo-
scopic treatmentofbenignbiliary strictures is significantly less
morbid than surgical and percutaneous approaches and has
reasonably low recurrence rates when an aggressive treat-
ment strategy is implemented. Benign biliary strictures re-
quire intervention to treat jaundice, chronic cholestasis, and
cholangitis, as well as to avoid the long-term development of
secondary biliary cirrhosis.2
Tomaximize treatmentefficacyandminimize stricture re-
currence, thestandardapproachtoendoscopic therapy isplace-
ment ofmultiple plastic stents in parallel after the stricture is
dilated using graduated bougie-type or hydrostatic balloon
catheters. Because the strictures are usually fibrotic and as-
sociated with a dilated bile duct, most benign strictures can-
not be fully dilated during the initial ERCP. This obligates an
average of 3 to 4 ERCPs to dilate, deploy stents, up-size, and
then ultimately remove all stents once the stricture has re-
solved. This strategy results in very high efficacy (80%-90%)
forpostoperativestricturesandmoderatelyhighefficacy (50%-
70%) for those caused by chronic pancreatitis.3,4
Despite the high success rate of multiple plastic stent
therapy, multiple treatment sessions are required. Because
placement of a single, fully covered, self-expandablemetallic
stent (cSEMS) results in radial dilation of a stricture equiva-
lent to that of at least 3 side-by-side plastic stents (which can-
not generally be placed during the initial ERCP), preliminary
studies including small clinical trials support the hypothesis
thatdeploymentof cSEMSwouldbebeneficial inpatientswith
benign strictures.5-9 We conducted an open-label, multi-
center, randomized clinical trial to test the hypothesis that
cSEMS would be noninferior to multiple plastic stents in the
first-line endoscopic treatment of benign bile duct strictures.
(See the trial protocol in Supplement 1 for details.)
Methods
The studywas executed at 8 regional referral centers for ERCP
and liver transplantation in theUnitedStates andUnitedKing-
dom, after local approval by their respective institutional re-
view boards. The US Food and Drug Administration moni-
tored this study under an Investigational Device Exemption
(G100118) because cSEMS are not approved for use in benign
bile duct strictures or for endoscopic retrieval except after im-
mediate deployment. Written informed consent was ob-
tained from all patients prior to the index ERCP procedure.
Eligible patients included those with a benign bile duct
stricture locatedat least2cmbelowthehepatic confluenceand
coupled with related signs or symptoms (eg, any elevation in
liver test results, jaundice, or cholangitis). A stricturewas de-
fined as any narrowing of the extrahepatic bile duct that was
less than 75% of the diameter of the unaffected duct; for ex-
ample, a 10-mmdiameterbileductwitha5-mmdiameter stric-
ture would be eligible. To our knowledge, no prior endo-
scopic studies have used a quantitative definition for benign
bile duct stricture, so this was based on expert consensus of
the study’s steering committee and approval from all partici-
pating investigators.The investigatorschoseaquantitativedefi-
nition in order to define stricture resolution using the same
fluoroscopiccriteria: the residualdiameterof thestricturemust
be 75%ormore of the duct above and below the stricture. Pa-
tientswhohadundergoneanytreatment to thestricturewithin
12 months of randomization, with the exception of a single,
bridgingplastic stent placedwithin 30days of liver transplan-
tation or while ruling out pancreatobiliary cancers, were ex-
cluded. Inaddition, thosehavingabileductdiameter less than
6mmabove or below the stricture to avoid oversizing the bile
duct (the smallest available cSEMS diameter in the United
States is 8mm), or if placement of a cSEMSwould overlap the
cystic duct in the setting of an intact gallbladder (due to a po-
tential risk for stent-induced acute cholecystitis), were ex-
cluded.Other exclusion criteria are summarized in eTable 1 in
Supplement 2.
Randomization
After obtainingwritten informedconsent, the investigatorde-
termined final eligibility after performing a cholangiogram to
confirm the presence of a benign bile duct stricture and to es-
tablish the absenceof exclusion criteria. Because chronicpan-
creatitis and postoperative strictures are inherently different
in their pathophysiology and response to endoscopic therapy,
we stratified randomization by these etiologies andby site, in
blocks of 4 to ensure balanced distribution of groups across
sites. The biostatisticianprovided a computer-generated ran-
domization sequence to each site, using opaque envelopes to
maintain allocation concealment. Once eligibility was con-
firmed, the site coordinator informed theERCPphysiciandur-
ing the procedure of treatment allocation (Figure 1). Because
follow-up was predicated on the type of stent used, patients
and investigators were not blinded to group assignment.
Interventions
Patients randomized to the plastic stent group were treated
using a standard algorithm (eFigure 1 in Supplement 2). Per
standardof care, the stricturewasdilated to themaximumsaf-
estdiameteraccording toendoscopist judgment, andthemaxi-
mumcumulativediameter of plastic stentswasdeployed.Re-
peat ERCPwasperformed3 to4months later,when all plastic
stents were removed and the stricture was assessed for reso-
lution. If the stricture persisted, then the cumulative diam-
eter of plastic stents was up-sized to the greatest extent fea-
sible. Until stricture resolution, ERCPs were repeated every 3
to 4 months with plastic stent up-sizing as needed.
Amongpatients randomized to receive cSEMS, the endos-
copist deployed a cSEMS (fully covered WallFlex, Boston
Scientific) of sufficient length to traverse the stricture and the
papilla (eFigure 1 in Supplement 2). The endoscopistwas per-
mitted to dilate the stricture before cSEMS deployment on an
as-needed basis. Tominimize cSEMSmigration, an 8-mmdi-
ameter cSEMS was used for bile ducts measuring 6 to 7 mm
and a 10-mm diameter cSEMS for bile ducts 8 mm or greater.
Because metallic stents have superior patency to multiple
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plastic stents, follow-up ERCPwas performed 6months after
randomization. For thosewith a persistent stricture at repeat
ERCP, the cSEMSwas replaced for another 6-month interval.
Inall cases,ERCPscouldbeperformedearlier thanperpro-
tocol when there was a clinical suspicion of premature stent
occlusion or migration. To ensure consistent practice across
sites, whenever stricture resolution occurred per study crite-
ria, all stents were removed and not replaced. For those with
a persistent stricture, stents were replaced and up-sized.
Follow-up andOutcomes
In all patients, treatment failure was defined as the presence
of a persistent stricture after 12months of endoscopic therapy
or if therewas 1major or 2minor stent-related adverse events
thatprecludedstudycontinuation (eg, stentmigration thatwas
complicated by acute cholangitis). A major or severe adverse
event was defined by the need for procedural intervention or
hospitalization; all other adverse eventswere classified asmi-
nor. A related adverse eventwas defined as one thatwas defi-
nitely or possibly related to the bile duct stents. In thosewho
achieved stricture resolutionwithin 12months of randomiza-
tion, follow-up continued for an additional 12 months after
stent removal to assess for stricture recurrence. Follow-up in-
cluded a telephone or in-person encounter to assess for signs
or symptomsof a benignbiliary stricture, includingbasic liver
test results.Wedefinedstricture recurrenceusing thesamecri-
teria for enrollment in the study: presence of a bile duct stric-
ture confirmed by ERCP with associated signs or symptoms.
Theprimaryoutcomewasstricture resolutionrate; thiswas
presented as an absolute rate after nomore than 12months of
endoscopic therapy. Technical success was defined as suc-
cessful endoscopic placement and removal of stents. Among
thosewhoachievedstricture resolution, recurrence rateswere
reported during the poststenting follow-up period (up to 12
months). Safety,withparticular emphasis on the rates of stent
migrationandstent-associatedstricturesbetweengroups,was
also evaluated. For those who achieved stricture resolution,
a process outcome was the requisite number of ERCPs to
achieve resolution.Acost analysiswasplannedasanother sec-
ondary outcome but has not yet been conducted.
Sample Size
Given thehighcosts and inconvenienceofmultipleERCPsand
infectious control concerns with duodenoscopes, and be-
cause we hypothesized that cSEMS would reduce the num-
ber of ERCPs required to achieve stricture resolution,we con-
sidered that cSEMScould replaceplastic stents as thepreferred
first-line stent for treating benign bile duct strictures if it re-
sulted in less thana−15%difference in treatmentefficacy (non-
inferioritymargin).Theoreticaldisadvantagesofmetallic stents
include their higher cost comparedwithplastic stents anddif-
ficulty with metallic stent removal during a follow-up ERCP.
Assuming a −15% noninferiority margin and a resolution rate
of 90% in the plastic stent group, and given no observed dif-
ference in stricture resolution rates in the cSEMS and plastic
stent groups, a sample size of 112 would result in 80% power
with a targeted significance level of .05. This also allowed for
anattrition rateof 10%fordropouts andpatients lost to follow-
up. The noninferiority margin was chosen to be −15% based
on the judgment of the study’s steering committee compris-
ing 5 board-certified gastroenterologists who are experts in
ERCP. The sample size was reduced to 112 from 250 after an
interimanalysis (77patients randomized) requestedbythedata
and safety monitoring board after 3 years of recruitment re-
vealed stricture resolution rates of greater than 90% in both
groups,without changing the targeted significance level (.05),
statistical power (80%), or attrition rate (10%).
Statistical Analysis
The primary analysis evaluated the noninferiority of cSEMS
to multiple plastic stents, which was determined based on a
Figure 1. Patient Flow Through the Biliary Stent Trial
254 Patients assessed for eligibility
142 Excluded (did not meet
inclusion criteria)
74 No bile duct stricture
5 No stricture-related signs
or symptoms
4 Intact gallbladder
2 Malignant stricture
19 Endoscopic therapy within
12 mo of randomization
17 Unaffected extrahepatic
bile duct <6 mm
12 Could not traverse
stricture with a guidewire
4 Stricture length >8 cm
5 Multiple concomitant
bile duct strictures
112 Randomized
41 Patients had stricture resolution
at 12 mo and entered additional
12-mo follow-up for stricture
recurrence
50 Patients had stricture resolution
at 12 mo and entered additional
12-mo follow-up for stricture
recurrence
36 Completed additional 12-mo
follow-up
5 Did not complete follow-up phase
of additional 12 mo after stent
removal
1 Lost to follow-up
4 Died
42 Completed additional 12-mo
follow-up
8 Did not complete follow-up phase
of additional 12 mo after stent
removal
4 Lost to follow-up
2 Died
2 Other reason
55 Randomized to receive plastic stents
55 Received plastic stents
57 Randomized to receive cSEMS
57 Received cSEMS
7 Discontinued study during
treatment (stenting) phase
1 Stricture found to be malignant
1 Protocol violation
1 Lost to follow-up
3 Died
1 Patient could not complete visits
due to illness
3 Discontinued study during
treatment (stenting) phase
1 Clinical reasons believed life
threatening by physician
1 Other reason
1 Stricture found to be malignant
48 Included in the primary analysis
at 12 mo
55 Included in other analyses
54 Included in the primary analysis
at 12 mo
57 Included in other analyses
cSEMS indicates fully covered, self-expandable metallic stent.
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2-samplebinomialnoninferioritytestatthe5%significancelevel.
Equivalently, the noninferiority was established if the lower
boundof the 1-sided95%confidence interval for thedifference
in resolution ratewas −15%or greater. Patientswith an incom-
plete treatment phase (9%) were excluded from the primary
analysis because of the uncertain status of their benign biliary
stricture (eg, died or lost to follow-upwhile stents remained in
place);wechoseamodifiedintent-to-treatapproachtominimize
biasingaconclusionfavoringnoninferiority.10,11Sensitivityanaly-
sis was performed to examine the noninferiority of the cSEMS
intheworst-casescenario,whereallpatientsexcludedfromthe
primaryanalysisbecauseofuncertainstricturestatuswerecon-
sideredtohaveresolution if theywere intheplasticstentsgroup
and no resolution if theywere in the cSEMS group.
Inadditiontotheprimaryanalysisofnoninferiority,weper-
formed a post hoc analysis to compare resolution rates be-
tween cSEMS and plastic stent groups using the Kaplan-Meier
method for time to resolution including all randomized pa-
tients in the study. Patients who had an incomplete treatment
(stenting)phasewerecensoredat the timeof studydiscontinu-
ation. The median (95% CI) number of days to resolution was
calculatedbasedon theKaplan-Meier plot. A log-rank testwas
performed to compare Kaplan-Meier estimates of resolution
rates. Post hoc analysis included comparison of the number of
days to resolution,whichwasperformedusingaWilcoxonrank
sum test. All post hoc analyses were 2-sided at the 5% signifi-
cance level, andadjustment formultiple comparisonswasper-
formed to account for having 3 outcomesusing theBonferroni
approach. These outcomes were also evaluated in the sub-
groupanalysesforpatientswithposttransplantandchronicpan-
creatitis–inducedstrictures,wheremultiple comparisonswere
not adjusted. Safety measures were evaluated using all ran-
domizedpatients. The studywasnot powered todetect differ-
ences in safety end points, recurrence rates, or number of
ERCPs required to achieve stricture resolution.
Baselinepatientcharacteristicswerepresentedusingmean
and standard deviations for normally distributed continuous
variables,median and range for nonnormally distributed con-
tinuous variables, and frequency andproportion for categori-
calvariables.ComparisonsbetweenthecSEMSandplastic stent
groupswere performedusing the 2-sample t test for normally
distributed continuous variables andWilcoxon rank sum test
for nonnormally distributed continuous variables. For cat-
egorical variables, Pearson χ2 test was used for variableswith
more than 2 categories and Fisher exact test was used for bi-
nary variables. All statistical analyses were performed using
SAS version 9.4 (SAS Institute).
Results
BetweenApril 2011 andSeptember2014, 254 individualswere
screenedforeligibilityand112were randomizedtoreceivemul-
tiple plastic stents (n = 55; mean [SD] age, 57 (11) years; 17
women [31%]) or cSEMS (n = 57;mean [SD] age, 55 [10] years;
19women [33%]) (Figure 1). Patient and stricture characteris-
tics are summarized in Table 1. The etiology of bile duct stric-
ture was balanced between treatment groups, with the ma-
jority (65%) being located at the biliary anastomosis after
orthotopic liver transplantation. Per study protocol, no pa-
tients hadmultiple plastic stents in place at the timeof enroll-
mentwhile 39%hada single bridgingplastic stent. During the
stenting period, 7 of 55 patients (12.7%) in the plastic stent
group and 3 of 57 patients (5.3%) in the cSEMS group ended
the studyduring the treatment (stenting) phase (Figure 1). The
primary outcome measure of stricture resolution for all re-
maining patients was available at 12 months, and these were
included in the primary analysis.
The majority of patients in both groups (multiple plastic
stents, 90.9% and cSEMS, 93.0%; −2.1% difference; 95% CI,
−12.2% to8%)underwent abiliary sphincterotomyat the time
of randomization or during an earlier ERCP (Table 2). Com-
paredwith cSEMS (14%), a significantly greater number of pa-
tients in the plastic stent group (80%, P < .001) underwent
balloon dilation during their index ERCP (66.0% difference;
95%CI,52.1%to79.9%).Most (73%)patients in theplastic stent
group received 2 ormore stents at enrollment, with amedian
cumulative diameter of 20 F (range, 7-30 F).
Stricture Resolution and Recurrence
Comparedwithmultipleplastic stents (41/48,85.4%), the reso-
lution ratewas 50of 54patients (92.6%) for cSEMSwith a rate
differenceof 7.2% (1-sided95%CI, −3.0%to;P < .001). Thus,
Table 1. Patient and Stricture Characteristics
Variable
Multiple Plastic
Stents
(n = 55)
cSEMS
(n = 57)
Age, mean (SD), y 56.7 (11) 54.5 (10.4)
Women, No. (%) 17 (30.9) 19 (33.3)
American Society of Anesthesiology
class ≥3, No. (%)a
42 (76.4) 39 (68.4)
Karnofsky performance status,
mean (SD)
79.3 (12.7) 78.9 (12.6)
Etiology of stricture, No. (%)
Postorthotopic liver transplant 36 (65.5) 37 (64.9)
Time since transplant,
median (range), mo
4 (1-96) 3 (1-44)
Chronic pancreatitis 17 (30.9) 18 (31.6)
Other postoperative injury 2 (3.6) 2 (3.5)
Stricture characteristics, median (range)
Distance of top of stricture
to the hepatic confluence, mm
34 (1-85) 36 (2.36-86)
Diameter of duct upstream
of stricture, mm
11 (5.7-13.0) 10 (6-18)
Diameter of duct downstream
of stricture, mm
8 (5.0-8.5) 7 (0-13.7)
Stricture length, mm 5 (0.7-38) 4 (1-32)
Previous cholecystectomy, No. (%) 42 (76.4) 43 (75.4)
Previous single plastic stent in place,
No. (%)
16 (29.1) 23 (40.4)
Total bilirubin, median (range), mg/dL 1.2 (0.4-20.7) 1.4 (0.4-17.4)
Alkaline phosphatase, median (range),
IU/L
317 (52-1027) 240 (14-1615)
Abbreviations: cSEMS, fully covered, self-expandable metallic stent.
SI conversion factors: To convert bilirubin to μmol/L, multiply by 17.104; alkaline
phosphatase to μkat/L, multiply by 0.0167.
a American Society of Anesthesiology (ASA) class ranges from 1 to 6; 1 represents
a normal, healthy patient and 6 a brain dead organ donor. ASA class 3 denotes a
patient with systemic disease that is not currently incapacitating.
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the null hypothesis that cSEMS would be less effective than
multiple plastic stents by at least −15%was rejected (because
the lower bound of the 1-sided 95% CI lies above −15%). Sen-
sitivity analysis assuming the worst-case scenario had simi-
lar findings. With a resolution rate of 87.7% (50/57) for the
cSEMSgroup and87.3% (48/55) for themultiple plastic stents
group, the 1-sided95%CI for thedifference in resolution rates
was −10% to  and P = .007, again demonstrating the nonin-
feriority of cSEMS. Despite patients in the plastic stent group
having an opportunity to achieve stricture resolution earlier
than patients in the cSEMS group (given their per-protocol
ERCP reassessments every 3-4months vs every 6months for
cSEMS),patientswhoreceivedacSEMSachievedstricture reso-
lution at a significantly faster rate, as demonstrated by the
Kaplan-Meier plot of time to resolution during the 12-month
stenting period (Figure 2). The estimated median number of
days to resolutionbasedon theKaplan-Meiermethodwas225
days (95%CI, 182 to 277 days) for the plastic stents group and
181 days (95% CI, 173 to 184 days) for the cSEMS group (log-
rank P = .006). Among patients who achieved stricture reso-
lution, thenumberofERCPs required toachieve stricture reso-
lutionwas significantly lower for those randomized to receive
cSEMSvsmultipleplastic stents (mean, 2.14vs 3.24;meandif-
ference, 1.10; 95% CI, 0.74 to 1.46; P < .001). These observa-
tions persisted in subgroup analyses of patients with post-
transplant (n = 73) and chronic pancreatitis–induced (n = 35)
strictures (eFigures 2 and 3 in Supplement 2).
Of those who achieved stricture resolution, 7 of 50 pa-
tients (14%) in the cSEMS group and 2 of 41 patients (4.9%) in
the plastic stent group developed a recurrent biliary stricture
(P = .18); of 9 recurrences, 6 occurred in post–liver transplant
cases.Amongpatients in the cSEMSgroup, 2of 7patientswith
recurrence had achieved stricture resolution after only 4 and
6 days of stent therapy, respectively. In these patients, a re-
peatERCPwasperformedforelevated liver test resultsatwhich
time the stent was removed; the bile duct stricture had re-
solved per study definition, so no stents were replaced per
study protocol. The remaining patients with stricture recur-
rence in both groups had undergone no less than 3months of
stent therapy.
Adverse Events
In patients who received plastic stents and cSEMS, all were
deployed successfully; there were no cases of failed cSEMS or
plastic stent removal during the first follow-up ERCP (techni-
cal success 100% for both groups). Similarly, there were no
cases of stent-induced strictures in either group that required
treatment. The mean number of adverse events per ERCP
was 0.23 for plastic stent vs 0.36 for cSEMS (−0.13 difference;
Figure 2. Time to Stricture Resolution
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cSEMS indicates fully covered, self-expandable metallic stent.
Table 2. Endoscopic Interventions During the Enrollment ERCP
Variable
Multiple Plastic Stents
(n = 55)
cSEMS
(n = 57) P Value
Biliary sphincterotomy, No. (%)
.49
No 5 (9.1) 4 (7)
Yes 31 (56.4) 27 (47.4)
Previous 19 (34.5) 26 (45.6)
Passage dilation, No. (%) 4 (7.3) 3 (5.3) .66
Balloon dilation, No. (%) 44 (80) 8 (14) <.001
Device’s maximal diameter for balloon dilation, No. (%)
.15
4 mm 1 (2.3) 1 (12.5)
6 mm 15 (34.9) 5 (62.5)
8 mm 22 (51.2) 2 (25)
>8 mm 5 (11.6) 0
cSEMS diameter, No. (%)
8 mm 17 (29.8)
10 mm 40 (70.2)
Cumulative plastic stent diameter, median (range), Fa 20 (7-30)
No. of stents, No. (%)b
1 15 (27.3) 57 (100)
2 35 (63.6) 0
3 5 (9.1) 0
Abbreviations: cSEMS, fully covered,
self-expandable metallic stent;
ERCP, endoscopic retrograde
cholangiopancreatography.
a Cumulative plastic stent diameter
represents the total diameter of
plastic stents deployed in parallel
during the first ERCP. For example,
two 10-F plastic stents equals a
cumulative diameter of 20 F.
bRepresents the total number
of stents deployed during
the first ERCP.
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95% CI, −0.29 to 0.03; P = .31), and the number of severe
adverse events per ERCP was 0.06 for plastic stents vs 0.13
for cSEMS (−0.07 difference; 95% CI, −0.17 to 0.04; P = .72).
Among those randomized to receive cSEMS, there were 16
cases of stent migration in 14 patients, all of which were dis-
tal to (below) the bile duct stricture (Table 3 and eTable 2 in
Supplement 2); 9 of 16 cases were observed at the time of
stricture resolution, and 7 of 16 cases occurred in the setting
of a persistent stricture. In 2 cases, stent migration was
severe because it required an urgent repeat ERCP for overt
biliary obstruction. By comparison, there were 10 cases of
plastic stent migration in 9 patients; 8 of 10 cases occurred in
the setting of a persistent biliary stricture, 1 of which required
urgent ERCP for overt biliary obstruction. We observed low
rates of post-ERCP pancreatitis (5.4%), secondary bile duct
changes (6.3%, none required treatment), and postprocedure
abdominal pain (15.2%) in both groups.
Among patients randomized to receive cSEMS (n = 57),
stentmigration occurredmore frequently in thosewith post-
transplant anastomotic strictures (13/14migration cases, 93%)
compared with all others (24/43 nonmigration cases, 56%;
P = .02). Although the sample size was limited, strictures as-
sociated with cSEMS migration were closer to the hilum
(34 mm [range, 19-86 mm] vs 40 mm [range, 2.4-86 mm];
P = .08), and thebileductbelowthe stricturewas larger (8mm
[range, 4.8-11 mm] vs 6mm [range, 0-13.7 mm]; P = .03). The
median lengthof thebileductstricturewassignificantlyshorter
in thosewithmigration (2mm[range, 1-10mm]vs9mm[range,
1-32 mm]; P < .001).
Discussion
The inventionof self-expandablemetallic stents addressedan
unmet need for durable biliary drainage in the setting of ma-
lignantbileductobstruction.Giventheir superiorpatencycom-
pared with plastic stents, self-expandable metallic stents are
preferred for the first-line treatment of extrahepatic malig-
nant bile duct strictures. Now, there is burgeoning interest in
using cSEMS for benign bile duct strictures because their ra-
dial force permits sustained andmaximal dilationof the stric-
ture at the time of initial ERCP as well as longer intervals be-
tween stent exchanges.
While numerous previous studies have evaluated
cSEMS as salvage and first-line options, these have been lim-
ited by retrospective and nonrandomized design, small
sample sizes, and inclusion of patients with partially treated
strictures.8,9,12-14 In this study, cSEMS were not inferior to
multiple plastic stents when used as the initial treatment
strategy but achieved resolution with significantly fewer
ERCPs.15 In addition, there were no failures to remove a
cSEMS at the first follow-up ERCP, possibly due to the study
enrollment criteria and planned 6-month indwell period.
While most prior cohort studies on this topic report very high
success rates with cSEMS removal, in a minority of cases
endoscopic removal may be difficult and require more than 1
ERCP to remove it successfully.8,9,13,16,17 Although this study
was not powered to detect differences in adverse event rates,
these data support prior observations that cSEMS can be
removed safely and without a higher risk of procedure-
related adverse events.
Recurrent Strictures
There was no statistically significant difference in the recur-
rence rate amongpatients randomized to receive cSEMS (14%
vs 5% for plastic stents; P = .15). This study was not ad-
equately powered to detect a difference in these rates, but it
is possible that the recurrence rate would be lower if cSEMS
were left in place for longer than 6 months. This will require
further study.
Table 3. Adverse Events
Adverse Event
Multiple Plastic Stents (n = 55) cSEMS (n = 57)
Total
No. of
Events
No. of
Patients
With Event
No. of
Severe
AEs,a
No. of
Patients
With
Severe AE
No. of
Related
AEsb
No. of
Patients
With
Related AE
Total
No. of
Events
No. of
Patients
With Event
No. of
Severe
AEs, a
No. of
Patients
With
Severe AE
No. of
Related
AEsb
No. of
Patients
With
Related AE
Stent migration 10 9 1 1 5 5 16 14 2 2 16 14
Abdominal pain 9 8 1 1 4 4 8 8 2 2 6 6
Premature stent
occlusion
Cholangitis 1 1 1 1 1 1 2 2 2 2 2 2
Bile duct
obstruction
1 1 0 0 0 0 1 1 0 0 1 1
Jaundice 1 1 0 0 0 0 1 1 1 1 0 0
Stent-induced
changes to the
bile duct
5 5 0 0 3 3 2 2 0 0 2 2
Post-ERCP
pancreatitis
3 3 0 0 3 3 3 3 0 0 2 2
All othersc 7 7 5 5 0 0 9 6 5 4 1 1
Total 37 27 8 8 16 14 42 28 12 9 30 23
Abbreviations: AE, adverse event; cSEMS, fully covered, self-expandable
metallic stent; ERCP, endoscopic retrograde cholangiopancreatography.
a Need for procedural intervention or hospitalization.
bDefinitely or possibly related to the bile duct stents or ERCP procedure.
c Refer to eTable 2 in Supplement 2 for details.
Metal Stents for Benign Biliary Strictures Original Investigation Research
jama.com (Reprinted) JAMA March 22/29, 2016 Volume 315, Number 12 1255
Downloaded From: http://jama.jamanetwork.com/ by a Indiana University School of Medicine User  on 10/06/2016
Copyright 2016 American Medical Association. All rights reserved.
StentMigration
Stent migration remains an important limitation of currently
available cSEMS and a focus of device development.18 This oc-
cursmorefrequently inpostoperativestricturesratherthanstric-
tures causedbychronicpancreatitis given theirmore focalnar-
rowingandproximal locationrelativetothemajorpapilla.There
were fewsymptomaticmigrations,but several requiredretreat-
mentbecause the stenthadmigratedbelowthe stricture, lead-
ing to recurrentobstruction.AcSEMSwithantimigrationprop-
ertiesmitigates the riskofmigrationbutmayposeahigher risk
ofsecondaryduct injury;alternatively, the ideal stentwouldmi-
grate or dissolve spontaneously after adequate stricture treat-
ment.Thereremainsaneedtodevelopnovel,expandablestents
that may be used in smaller-diameter ducts and without the
need for routine follow-up ERCPs to retrieve them. Stent mi-
gration is alsoan issuewithmultipleplastic stents.Whenusing
either type of stent, a biliary sphincterotomy is almost univer-
sallyperformedto facilitateplacementofmultipleplastic stents
side-by-side or a large-diameter cSEMS. There are no conclu-
sive data that placing a cSEMS ormultiple plastic stents across
an intact sphincterofOddi increases the riskofpost-ERCPpan-
creatitis or other complications.
Limitations
This studywas limited by the absence of a cost analysis com-
paring the 2 treatment strategies. In addition, this study was
limited by its open-label design and variable period of fol-
low-up according to treatment allocation. The steering com-
mittee determined these limitations were unavoidable; uni-
versal follow-up at 3 months would have been a suboptimal
duration of cSEMS indwell whereas delayed follow-up at 6
months for patients in the plastic stent groupwould have de-
layed the often inevitable need for stent up-sizing while ex-
posing patients to a higher risk of premature stent occlusion.
Tominimize outcome bias in an open-label study, a quantita-
tive definition was used for stricture resolution, and the pro-
tocol actually favors theplastic stent strategy in termsof faster
time to resolution; patients randomized to receive multiple
plastic stentshadanopportunity tomeet thedefinitionof stric-
ture resolution after 3months, whereas patients randomized
to receive cSEMS generally did not return until 6 months un-
less therewasaclinical indicationtoperformERCPearlier (such
as elevation in liver test results). Still, a quantitative defini-
tion of stricture resolution remains susceptible to human in-
terpretation of the fluoroscopic images.
Because the enrollment criteria included benign biliary
strictures fromchronic pancreatitis and postoperative etiolo-
gies, this study was not adequately powered to conduct sub-
group analyses to compare the efficacy of cSEMS vs multiple
plastic stents ineachentity.For thosewithposttransplant stric-
tures, the observed resolution rate after 12 months of stent-
ingwasnoninferior (cSEMS,91.7%vsplastic, 93.9%), but there
was a higher recurrence rate among those randomized to re-
ceive cSEMS (5/33 [15.2%]vs 1/30 [3.3%] for plastic). Theseob-
servations are limited by the small number of recurrent stric-
tures yet are in linewith prior observations.19 In addition, the
investigators chose anoninferioritymarginof −15%after care-
ful discussion by members of the study steering committee.
A smaller noninferioritymarginwouldhave strengthened the
conclusionsbutwouldhavebeenunlikely tochange themsub-
stantially because the observed margin (+7.2%) actually fa-
vored the cSEMS group.
It is not clear how long to keep stents in place. Longer in-
dwell periods for cSEMS may increase the risk for secondary
bile duct injuries, migration, and stent removal, while pro-
longed indwell periods for plastic stents (after stricture reso-
lution) increase the risk of premature stent occlusion and ex-
cess utilization of ERCPs. The optimal indwell period likely
depends on the etiology of biliary stricture. Because the ob-
jective was to study first-line treatments for bile duct stric-
ture and avoided refractory or recurrent strictures that often
obligate more aggressive and longer periods of stenting, the
studyprotocol reflects standardpractice.1 In addition, the ob-
served resolution and recurrence rateswere comparablewith
those in previous studies.3,20
The generalizability of these findings was compromised
by the study’s strict enrollment criteria, particularly avoiding
patientswith small (<6mm)extrahepatic bile ducts and those
inwhomthe cystic ductmighthavebeenoccludedbyanover-
lapping cSEMS. While the risk of SEMS-induced acute chole-
cystitis is controversial in studies evaluating SEMS for malig-
nant biliary strictures, the authors determined that a more
cautious approach in this patient population would be pru-
dent. The safety of cSEMS in these 2 settings will require fur-
ther study.
Thepoststenting follow-upperiodof 12monthsmaybe in-
adequate fordeterminingoverall stricture recurrence rates.We
chosea12-monthfollow-upperiodbecauseofassumptions that
delayed stricture recurrence rates would be less likely to dif-
fer across treatment strategies. Thiswill require further study.
Conclusions
Amongpatientswithbenignbiliary stricturesof6mmor larger
inwhomthe coveredmetallic stentwouldnotoverlap the cys-
tic duct, cSEMS were not inferior to multiple plastic stents in
achieving stricture resolution after no more than 12 months
of endoscopic therapy. Metallic stents should be considered
an appropriate option in patients such as these.
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